Edition:
United States

ArQule Inc (ARQL.O)

ARQL.O on Consolidated Issue listed on NASDAQ Global Market

1.14USD
24 Mar 2017
Change (% chg)

$-0.05 (-4.20%)
Prev Close
$1.19
Open
$1.19
Day's High
$1.19
Day's Low
$1.13
Volume
383,391
Avg. Vol
171,886
52-wk High
$2.17
52-wk Low
$1.13

Latest Key Developments (Source: Significant Developments)

Arqule posts Q4 loss per share of $0.10
Tuesday, 7 Mar 2017 07:00am EST 

Arqule Inc : Arqule reports fourth quarter and full year 2016 financial results . Q4 loss per share $0.10 . Q4 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S . Sees FY 2017 loss per share $0.42 to $0.45 . Arqule inc- for 2017, Arqule expects net use of cash to range between $25 and $27 million . Arqule expects to end 2017 with between $18 and $20 million in cash and marketable securities .FY 2017 earnings per share view $-0.42 -- Thomson Reuters I/B/E/S.  Full Article

Daiichi Sankyo and ArQule's carcinoma drug failed in late-stage trial
Friday, 17 Feb 2017 06:00am EST 

ArQule Inc - : Daiichi Sankyo and Arqule announce the completion of the metiv-hcc phase 3 study of tivantinib in second-line treatment of met-overexpressing hepatocellular carcinoma . Study of tivantinib in hepatocellular carcinoma (hcc) did not meet its primary endpoint of improving overall survival .Primary endpoint of study is overall survival.  Full Article

Arqule enters into capital on demand sales agreement with Jonestrading Institutional Services LLC on Oct. 25
Wednesday, 26 Oct 2016 06:18am EDT 

Arqule Inc : Arqule- On October 25, 2016, co entered into a capital on demand!" sales agreement with Jonestrading Institutional Services LLC - sec filing .Arqule- May sell from time to time through agent shares of co's common stock, par value $0.01 per share with an aggregate sales price of up to $30 million.  Full Article

Arqule Inc files for mixed shelf of upto $100 million - SEC filing
Friday, 2 Sep 2016 08:07am EDT 

Arqule Inc : Files for mixed shelf of upto $100 million - SEC filing Source: (http://bit.ly/2bJGGEw) Further company coverage: [ARQL.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Arqule Q2 loss per share $0.07
Wednesday, 3 Aug 2016 07:00am EDT 

Arqule Inc : Q2 loss per share $0.07 . Q2 earnings per share view $-0.08 -- Thomson Reuters I/B/E/S . Arqule reports second quarter 2016 financial results . Q2 revenue $1.072 million versus i/b/e/s view $1.1 million .Q2 earnings per share view $-0.08, revenue view $1.1 million -- Thomson Reuters I/B/E/S.  Full Article

Arqule Inc gives FY 2016 guidance
Wednesday, 4 May 2016 07:00am EDT 

Arqule Inc:Expects FY 2016 revenues to range between $4 and $5 million.Expects FY 2016 net loss to range between $24 and $27 million, and net loss per share to range between $(0.34) and $(0.39).  Full Article

ArQule Inc presents results from phase 1b expansion study of ARQ 092
Monday, 28 Sep 2015 07:30am EDT 

ArQule Inc:Presents results from phase 1b expansion study of ARQ 092 at 2015 European cancer conference.After one pr was observed in a patient with chronic lymphocytic lymphoma, the study was expanded to phase 1b with a focus on lymphoma.Says 25 patients have been treated in the study, and four partial responses (prs) have been observed.Says mutation status for a fourth patient could not be determined.  Full Article

ArQule Inc APPOINTS ROBERT J. WEISKOPF AS CHIEF FINANCIAL OFFICER
Monday, 1 Jun 2015 07:30am EDT 

ArQule Inc:Appoints Robert J. Weiskopf as chief financial officer.Weiskopf will retain the title of treasurer.Weiskopf was previously vice president of finance, corporate controller and treasurer of Arqule.  Full Article

Arqule and Beryllium announces collaborative research and development agreement
Tuesday, 5 May 2015 08:30am EDT 

Arqule Inc and Beryllium Discovery Corp:Announces collaborative research and development agreement to identify and unlock the therapeutic potential of small molecule compounds by combining ArQule's chemistry and drug development expertise with Beryllium's discovery platforms.The Beryllium platforms integrate structure-guided drug discovery, biophysics and cell biology.The therapeutic targets to be pursued by the parties include PD-1 (programmed cell death protein 1) and PDL-1 (programmed death ligand 1), two proteins believed to play major roles in suppressing or limiting the response of the immune system.Molecules that bind to and inhibit the effects of these targets may help direct the immune system to combat a variety of tumors.  Full Article

More From Around the Web

BRIEF-Arqule posts Q4 loss per share of $0.10

* Arqule reports fourth quarter and full year 2016 financial results